PMID- 15694996
OWN - NLM
STAT- MEDLINE
DCOM- 20050329
LR  - 20071114
IS  - 0198-8859 (Print)
IS  - 0198-8859 (Linking)
VI  - 66
IP  - 2
DP  - 2005 Feb
TI  - Characterization of host immunity to cytomegalovirus pp150 (UL32).
PG  - 116-26
AB  - The basic phosphoprotein 150 (pp150), the product of UL32 (unique long domain 32) 
      gene of human cytomegalovirus (CMV), is an abundant component of the viral 
      tegument and a target of human leukocyte antigen (HLA)-restricted cytotoxic T 
      cells (CTLs) after infection. Identification of minimal cytotoxic epitopes (MCEs) 
      from this CMV protein is of importance for peptide-based vaccines and 
      immunotherapeutic approaches. Several pp150-specific CTL clones were derived from 
      peripheral blood mononuclear cells of healthy CMV-positive donors with autologous 
      fibroblasts infected either with CMV AD169 or with a recombinant vaccinia virus 
      expressing full-length pp150 protein. HLA A*0301- and HLA A*6801-restricted CD8+ 
      pp150 T-cell clones derived from different donors were found to efficiently kill 
      autologous CMV-infected fibroblasts. Fine mapping of each MCE first used a T-cell 
      epitope prediction algorithm. Overlapping peptides within the recognized regions 
      were screened. The analysis identified pp150(792-802) and pp150(945-955) as MCEs 
      for the HLA A*6801 and the HLA A*0301 pp150 clones, respectively. In vitro 
      stimulation by recombinant modified vaccinia Ankara virus expressing full-length 
      pp150 elicited high frequencies of CMV-CTL and interferon gamma production 
      specific for the MCE identified in all subjects. The consistent presence of pp150 
      T cells in CMV-exposed individuals supports a role for this antigen in shaping 
      the antiviral CTL response and indicates that pp150 could be a pivotal 
      constituent of prophylactic and therapeutic CMV vaccines.
FAU - La Rosa, Corinna
AU  - La Rosa C
AD  - Laboratory of Vaccine Research, Beckman Research Institute of the City of Hope, 
      Duarte, CA 91010, USA.
FAU - Wang, Zhongde
AU  - Wang Z
FAU - Lacey, Simon F
AU  - Lacey SF
FAU - Markel, Susan F
AU  - Markel SF
FAU - Sharma, Madeva C
AU  - Sharma MC
FAU - Martinez, Joybelle
AU  - Martinez J
FAU - Lalimarmo, Maria M
AU  - Lalimarmo MM
FAU - Diamond, Don J
AU  - Diamond DJ
LA  - eng
GR  - AI52065/AI/NIAID NIH HHS/United States
GR  - CA33572/CA/NCI NIH HHS/United States
GR  - M01-RR0043-38/RR/NCRR NIH HHS/United States
GR  - P01-CA30206/CA/NCI NIH HHS/United States
GR  - R01-CA77544/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Hum Immunol
JT  - Human immunology
JID - 8010936
RN  - 0 (HLA Antigens)
RN  - 0 (Phosphoproteins)
RN  - 0 (Receptors, Antigen, T-Cell, alpha-beta)
RN  - 0 (Vaccines, DNA)
RN  - 0 (Viral Matrix Proteins)
RN  - 0 (pp150 protein, Cytomegalovirus)
SB  - IM
MH  - Clone Cells
MH  - Cytomegalovirus/immunology
MH  - Cytomegalovirus Infections/immunology
MH  - Cytotoxicity, Immunologic
MH  - *Epitope Mapping
MH  - HLA Antigens/immunology
MH  - Humans
MH  - Phosphoproteins/*genetics/*immunology
MH  - Receptors, Antigen, T-Cell, alpha-beta
MH  - T-Lymphocytes, Cytotoxic/immunology/*virology
MH  - Vaccines, DNA/*immunology
MH  - Vaccinia virus
MH  - Viral Matrix Proteins/*genetics/*immunology
EDAT- 2005/02/08 09:00
MHDA- 2005/03/30 09:00
CRDT- 2005/02/08 09:00
PHST- 2004/08/03 00:00 [received]
PHST- 2004/10/12 00:00 [revised]
PHST- 2004/10/18 00:00 [accepted]
PHST- 2005/02/08 09:00 [pubmed]
PHST- 2005/03/30 09:00 [medline]
PHST- 2005/02/08 09:00 [entrez]
AID - S0198-8859(04)00653-6 [pii]
AID - 10.1016/j.humimm.2004.10.008 [doi]
PST - ppublish
SO  - Hum Immunol. 2005 Feb;66(2):116-26. doi: 10.1016/j.humimm.2004.10.008.